Literature DB >> 7822024

Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.

S Mukherjee1, S C Lee, A Casadevall.   

Abstract

Monoclonal antibodies (MAbs) to the capsular polysaccharide of the pathogenic fungus Cryptococcus neoformans can prolong survival and decrease organ fungal burden in experimental murine cryptococcosis. To investigate the mechanism of antibody-mediated protection, the interaction of C. neoformans and murine macrophage-like J774.16 cells was studied in the presence and absence of MAbs differing in isotype. Immunoglobulin G2a (IgG2a) and IgG2b isotype switch variants were isolated from an IgM hybridoma to complete the IgG subclass set. IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA MAbs were studied for their ability to promote phagocytosis and reduce the number of CFU in C. neoformans and J774.16 cell cocultures. The MAbs in this set had similar if not identical fine specificities and were derived from a single B cell. All isotypes promoted phagocytosis; however, the IgG subclasses were more effective opsonins than IgM or IgA. All isotypes enhanced J774.16 anti-C. neoformans activity in vitro, as measured by a reduction in the number of CFU. The IgG1 MAbs were consistently more active in promoting opsonization and reducing the number of CFU. Addition of IgG1 MAb to C. neoformans and J774.16 cocultures resulted in rapid reduction in the number of CFU, which is consistent with fungal killing. Electron microscopy revealed that MAb-opsonized C. neoformans cells were internalized and appeared damaged. Administration of IgM, IgG1, IgG2a, and IgG2b isotype switch variant MAbs revealed that the IgG2a and IgG2b subclasses were the most and least effective isotypes, respectively, in prolonging survival in an intraperitoneal murine infection model. The results indicate that murine antibody subclasses differ in their ability to enhance macrophage anti-C. neoformans activity and suggest that antibody enhancement of macrophage function is a mechanism by which antibodies modify infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822024      PMCID: PMC173034          DOI: 10.1128/iai.63.2.573-579.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Passive immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  Proc Soc Exp Biol Med       Date:  1958-07

Review 2.  Serum therapy revisited: animal models of infection and development of passive antibody therapy.

Authors:  A Casadevall; M D Scharff
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

3.  Complement depletion in cryptococcal sepsis.

Authors:  A M Macher; J E Bennett; J E Gadek; M M Frank
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

4.  Role of macrophages in immunity and pathogenesis of experimental cryptococcosis induced by the airborne route--Part II: Phagocytosis and intracellular fate of Cryptococcus neoformans.

Authors:  R M Karaoui; N K Hall; H W Larsh
Journal:  Mykosen       Date:  1977-11

Review 5.  The biology and pathology of Fc receptors.

Authors:  M Sandor; R G Lynch
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

6.  Effect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes.

Authors:  S M Levitz; A Tabuni; C Treseler
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Antimicrobial proteins of murine macrophages.

Authors:  P S Hiemstra; P B Eisenhauer; S S Harwig; M T van den Barselaar; R van Furth; R I Lehrer
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide.

Authors:  X Jiang; B Leonard; R Benson; C L Baldwin
Journal:  Cell Immunol       Date:  1993-10-15       Impact factor: 4.868

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.

Authors:  S Mukherjee; S Lee; J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more
  63 in total

1.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model.

Authors:  Sumit Ghosh; Scott A Hoselton; Jane M Schuh
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

Review 3.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

4.  Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice.

Authors:  Eric Yager; Constantine Bitsaktsis; Bisweswar Nandi; Jere W McBride; Gary Winslow
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans.

Authors:  C Luberto; D L Toffaletti; E A Wills; S C Tucker; A Casadevall; J R Perfect; Y A Hannun; M Del Poeta
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

6.  Detection of cell wall galactomannoprotein Afmp1p in culture supernatants of Aspergillus fumigatus and in sera of aspergillosis patients.

Authors:  Patrick C Y Woo; Che-Man Chan; Andy S P Leung; Susanna K P Lau; Xiao-Yan Che; Samson S Y Wong; Liang Cao; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Matthew S Marks; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.